7/12
Powered by Foleon

Create the content your audience craves.

Find out more
  • Pages
  • Editions
01 Welcome
02 Introduction
03 #1 DEP and AI
04 #2 Radiogligand
05 #3 Living Cancer Cell Liquid
06 #4 Solid Tumor
07 #5 AI Driven SaaS
08 #6 Nanoparticles Reprogram
09 #7 Dual Checkpoint
10 #8 Approved HER2
11 #9 Biosimilar
12 #10 Big Data

#5 AI Driven SaaS Model Approved for Prostate Cancer Diagnosis

Oncology Advancements: Top 10 of 2022

ProstatIDâ„¢ combines AI with traditional MRI scanning to recognize and detect suspicious legions.

Why is this significant?

This AI software not only can assess visible features, such as brightness and grayscale, but also those invisible to the human eye such as pixel-by-pixel texture, 3D voxel texture and infinite feature weighting testing and validation.

The potential combination of AI and diagnostics could advance screening and early detection.

Why Could this Impact Care?

This machine learning algorithm assists in making a cancer diagnosis by producing a colorized map of normal and abnormal tissue. The program assigns a probability score to each lesion, which has the potential to be expanded across other cancer types (breast in design now).

This clearance shows the trend toward providing AI-assisted clinical decision support as a software-as-a-service offering to radiologists who can connect to a cloud-based server, upload the MRI, and receive an AI-generated report in less than an hour. This is a potential gamechanger to:

  • increasing global access to high quality care
  • decreasing health inequity due to location or socio-economic status
  • providing solutions for the global lack of physicians
  • enabling early diagnosis of cancer by detecting changes that are not seen by the human eye
  • decreasing time from diagnosis to treatment

Bot Image received FDA clearance for an artificial intelligence-driven software used to improve the accuracy and speed of prostate cancer detection.

Sources:

FDA clears AI software for spotting prostate cancer in MRI scans
AI-Driven Software Based Off NIH Algorithm Receives FDA Clearance in Detection and Diagnosis of Prostate Cancer